Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PLSE · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Treating PHPT With the nPulse™ Vybrance™ PE System NCT07912892 · Primary Hyperparathyroidism Ultrasound-Guided Parathyroid Nanosecond Pulsed Field Ablat… | PLSE Pulse Biosciences, Inc. | Not applicable | Not yet recruiting | 15 | Nov 30, 2027 | Registry ↗ |
| Oct 28, 2026 | Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System NCT07287176 · Thyroid Nodule, Thyroid Goiter nPulse Vybrance Percutaneous Electrode System | PLSE Pulse Biosciences, Inc. | Not applicable | Active, not recruiting | 103 | Apr 30, 2027 | Registry ↗ |
| Sep 9, 2026 | CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibr… NCT06959121 · Atrial Fibrillation, Maze Procedure CellFX® nsPFA™ Cardiac Surgery System | PLSE Pulse Biosciences, Inc. | Not applicable | Recruiting | 135 | Apr 2027 | Registry ↗ |
| May 6, 2026 | NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System NCT07018596 · Atrial Fibrillation Paroxysmal, Cardiac Ablation CellFX nsPFA Cardiac Catheter System | PLSE Pulse Biosciences, Inc. | Not applicable | Recruiting | 215 | Oct 2026 | Registry ↗ |
| May 5, 2026 | CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial… NCT06696170 · Atrial Fibrillation Paroxysmal, Cardiac Ablation CellFX nano-pFA 360 Endocardial Ablation Catheter System | PLSE Pulse Biosciences, Inc. | Not applicable | Recruiting | 60 | Jun 25, 2026 | Registry ↗ |
| Jan 12, 2026 | CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation NCT06355063 · Atrial Fibrillation, Surgery CellFX® nsPFA™ Cardiac Surgery System | PLSE Pulse Biosciences, Inc. | Not applicable | Recruiting | 30 | Dec 31, 2026 | Registry ↗ |
| Nov 21, 2024 | CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules NCT06117085 · Thyroid Nodule (Benign) CellFX® Percutaneous Electrode (PE) System | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 30 | Nov 18, 2024 | Registry ↗ |
| Apr 25, 2024 | Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions NCT04539886 · Skin Lesion, Skin Abnormalities CellFX System, Intralesional Electrodesiccation | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 60 | Feb 2, 2021 | Registry ↗ |
| Apr 12, 2024 | Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia NCT03612570 · Skin Lesion, Skin Abnormalities Nano-Pulse Stimulation Device | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 72 | Sep 5, 2018 | Registry ↗ |
| Nov 24, 2023 | CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts NCT04738734 · Warts, Warts Hand CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 150 | Dec 15, 2021 | Registry ↗ |
| Oct 30, 2023 | Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study NCT04253418 · Sebaceous Hyperplasia, Skin Abnormalities Nano-Pulse Stimulation (NPS) | PLSE Pulse Biosciences, Inc. | Not applicable | Terminated | 125 | May 14, 2020 | Registry ↗ |
| Oct 30, 2023 | Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study NCT04249115 · Lesion Skin, Seborrheic Keratosis Nano-Pulse Stimulation (NPS) | PLSE Pulse Biosciences, Inc. | Not applicable | Terminated | 175 | Aug 13, 2020 | Registry ↗ |
| Aug 22, 2023 | Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study NCT03846531 · Lesion Skin, Seborrheic Keratosis Nano-Pulse Stimulation (NPS) | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 58 | Nov 13, 2017 | Registry ↗ |
| Jul 27, 2023 | CellFX System for the Treatment of Cutaneous Non-Genital Warts NCT04554394 · Warts, Warts Hand CellFX Device | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 62 | Jun 9, 2020 | Registry ↗ |
| Jan 11, 2023 | CellFX Treat & Resect Low-Risk BCC Feasibility Study NCT04918381 · BCC - Basal Cell Carcinoma, BCC CellFX System | PLSE Pulse Biosciences, Inc. | Not applicable | Completed | 30 | Mar 2, 2022 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:27 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances